Case Reports
doi: 10.1016/j.lungcan.2012.02.003.
Epub 2012 Mar 3.
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
Affiliations
- PMID: 22385925
- DOI: 10.1016/j.lungcan.2012.02.003
Item in Clipboard
Case Reports
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
Lung Cancer.
2012 May.
Abstract
Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386065 Review.
-
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Curr Opin Investig Drugs. 2010. PMID: 21154129 Review.
-
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Clin Pharmacol Ther. 2014 Jan;95(1):15-23. doi: 10.1038/clpt.2013.200. Epub 2013 Oct 3. Clin Pharmacol Ther. 2014. PMID: 24091716 Review.
-
Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.Onkologie. 2013;36(6):342-7. doi: 10.1159/000351163. Epub 2013 Apr 30. Onkologie. 2013. PMID: 23774148
-
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.Lung Cancer. 2012 Jun;76(3):387-92. doi: 10.1016/j.lungcan.2011.11.022. Epub 2011 Dec 18. Lung Cancer. 2012. PMID: 22186628
Cited by
-
Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.Oncotarget. 2016 Dec 20;7(51):84666-84674. doi: 10.18632/oncotarget.13179. Oncotarget. 2016. PMID: 27835868 Free PMC article.
-
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.Front Oncol. 2018 Jul 27;8:278. doi: 10.3389/fonc.2018.00278. eCollection 2018. Front Oncol. 2018. PMID: 30140655 Free PMC article. Review.
-
Sustained release of methotrexate through liquid-crystalline folate nanoparticles.J Mater Sci Mater Med. 2014 Sep;25(9):2095-109. doi: 10.1007/s10856-014-5257-6. Epub 2014 Jun 22. J Mater Sci Mater Med. 2014. PMID: 24952639
-
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.Int J Mol Sci. 2020 Apr 30;21(9):3157. doi: 10.3390/ijms21093157. Int J Mol Sci. 2020. PMID: 32365759 Free PMC article. Review.
-
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.RSC Adv. 2019 Jun 7;9(31):17921-17932. doi: 10.1039/c9ra02258a. eCollection 2019 Jun 4. RSC Adv. 2019. PMID: 35520562 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
